I've check FDA, FDA Taiwan and Italian Ministry of Health websites and no luck to finding any approvals.
That doesn't surprise me though and doesn't mean one of them have approved.
But a very optimistic what if....
Post the EGM Yacovs $10m line of credit has been payout with stock. meaning there should now be c$10m available as we haven't been informed this facility has been withdrawn. Yacov could use these funds to repay the Manga CN and thus less dilution at these levels.
Then, IMO this trading halt is in regards to Taiwan and in turn will result in an agreement with FCL. Hopefully all announced at the same time.
This contract with FCL will then be exchange for cash with the Israel insurance company.
Thus, balance sheet issues fixed, less dilution, first product orders, factory start up and cash in the bank.
Share price will be much much higher.
Then we look forward to:
Italian registration and Meditel contract FDA OTC and patch approvals NMPA approvals for prizma and patch
All happening IMO
GMV Price at posting:
4.5¢ Sentiment: Buy Disclosure: Held
